LIFE sciences firm Pharmacells is set to extend its service into Europe and the Middle East as the stem cell specialist enters what is expected to be a rapid period of expansion.
The Glasgow-based company is currently negotiating a partnership that will see its Oristem services introduced into Spain and Portugal in the coming months.
Launched in June, Oristem is a service that allows adults to store their own stem cells to help treat diseases they may get later in life.
Athol Haas, chief executive and co-founder of Pharmacells, has just returned from Dubai and Abu Dhabi, where he was talking to healthcare providers about partnerships similar to its Spanish deal.
The trip followed a hectic week in London for the biotech executive, in which he was locked in discussions to extend Oristem's reach.
"Right now we are in the process of growing that network and growing it in a most prodigious fashion," he said.
Stem cells have the potential to grow into any of the 250 types of cell found in the human body. Scientists are using stem cells to create treatments for injuries and illnesses that are currently incurable.
Oristem takes "young blastomere-like stem cells (BLSCs) from a sample of blood, a much less invasive procedure than more costly techniques to extract stems that have already begun developing".
Formed in 2008, Pharmacells is majority-owned by founders Haas and chief scientific officer Neil Fell, who stumped up their own cash to buy the rights to the Oristem technology.
The business has raised a relatively modest £500,000 in two rounds of funding from Grampian BioPartners, the Scottish Co-investment Fund and small private investors.
The firm, which turns over about £500,000 a year, is set to move to the BioCity Scotland facility at Newhouse in Lanarkshire in March.
Pharmacells will hire two people as a result of the move, taking its headcount to eight.
Commercial Collaboration Deal for (Oral) Lynovex® | 5th August 2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria | 18 June 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance | 7th June 2016
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010
Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016
NovaBiotics Wins Investment of the Year Award
5th February 2016
Launch of the BEAM Alliance
9th June 2015
NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015
Showcases increasing investor interest in the global stem cell sector
22nd September 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year
27th June 2014